Participate in Multiple Sclerosis Clinical Trial Today
Active and recruiting trials
-
The REMODEL-2 Study is a Phase 3b study using remibrutinib for those with Relapsing Multiple Sclerosis. Approximately 800 participants are expected to take part in North America and Europe.
For more information, please visit clinicaltrials.gov.
If you are interested in participating, please contact Yousri YBenchaar@gengepartners.com
-
More info to come
Active but not recruiting trials
Upcoming trials
If you would like to hear about more about our current or upcoming neurological clinical trials in Montreal please contact us at: info@gengepartners.com
“If we’re not in the beginning for rare disease, we may simply be too late for our patients to get the benefit of these new therapies.”
-Angela Genge
-
Our mission
To improve patient health and well-being by conducting cutting-edge clinical research. We strive to foster a culture of innovation, collaboration, and excellence in all aspects of our research, and to contribute to the global effort to improve healthcare for all.
-
Our vision
To be a leading force in advancing medical knowledge and improving patient care through innovative and ethical clinical research
-
Our future
GP Research will continue to be at the forefront of clinical research, utilizing the latest technologies and methodologies to bring new treatments and therapies to patients in need. Our commitment to patient safety, scientific rigor, and ethical conduct will remain steadfast, as we work to improve healthcare for all and make a lasting impact on the field of medicine.
Our facility:
GP Research @ Glen
5100 Boul. de Maisonneuve Ouest, 6th floor
Montreal, QC H4A 3TA